|Bid||60.52 x 1400|
|Ask||61.00 x 800|
|Day's range||58.83 - 64.00|
|52-week range||21.06 - 74.32|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||41.24|
|Earnings date||01 Nov 2022 - 04 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||73.78|
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.